Cover Image
市場調查報告書

Heplisav(B型肝炎病毒(HBV)預防疫苗)- 預測與市場分析

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 299166
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
Heplisav(B型肝炎病毒(HBV)預防疫苗)- 預測與市場分析 Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 91 Pages
簡介

B型肝炎是B型肝炎病毒(HBV)所引起的急性或慢性肝炎。全球HBC感染者約20億,HBV相關的肝病造成每年約60萬人的死亡。由於基因重組HBV表面抗原(HBsAg)疫苗的出現,大大減輕了過去二十年疾病的負擔,但仍留有成人方面病毒攝取及有效性的疑問。

本報告提供Dynavax Technologies所開發的佐劑(抗原免疫疾病增強劑)開發疫苗候補──Heplisav調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,主要國家的銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 概要
  • 病因·病理生理學
  • 症狀
  • 預測

第4章 疫苗接種宣導與接種率

  • 概要

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 機會及未滿足需求

  • 概要
  • 疫苗免疫抗原性的增加
  • 疫苗接種率的增加
  • 患者意識的提升
  • 醫生教育素質的提升
  • 高成本效益的疫苗

第7章 開發平台評估

  • 概要

第8章 Heplisav

  • 概要
  • 免疫抗原性
  • 安全性
  • 給藥·處方
  • 潛在的臨床性地位
  • 潛在的商業性地位
  • 價格與回本
  • SWOT分析
  • 預測

第9章 附錄

圖表

目錄
Product Code: GDHC336DFR

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Heplisav [Hepatitis B vaccine, 1018 ISS immunostimulatory oligonucleotide with HBsAg (HBsAg-1018)] is Dynavax Technologies' adjuvanted pipeline vaccine candidate that guards adults against acute and chronic infections caused by all known strains of HBV, with a particular emphasis on protecting adults that have failed to achieve seroconversion from the currently licensed HBV vaccines. With Heplisav, Dynavax hopes to address a key clinical unmet need in the treatment landscape while simultaneously improving HBV vaccination coverage in adults.

Scope

  • Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Heplisav including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Heplisav for top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, UK, Japan and Canada.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Heplisav performance
  • Obtain sales forecast for Heplisav from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, UK, Japan and Canada).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Increased Vaccine Immunogenicity
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Increased Vaccination Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Patient Awareness
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Physician Education
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. More Cost-Effective Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview

8. Heplisav

  • 8.1. Overview
  • 8.2. Immunogenicity
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9 Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Patient Populations Targeted for Vaccination
    • 9.4.2. Vaccination Coverage Rates
    • 9.4.3. Vaccinated Patients
    • 9.4.4. Regulatory Approval vs. Advisory Committee Recommendation
    • 9.4.5. Vaccines Included
    • 9.4.6. General Pricing Assumptions
    • 9.4.7. Pricing of Pipeline Vaccines
  • 9.5. Physicians and Specialists Included in this Study
    • 9.5.1. Interviews of Key Opinion Leaders (KOLs)
    • 9.5.2. Online Survey of High-Prescribing Physicians (non-KOLs)
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Director
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Modes of HBV Transmission
  • Table 2: HBV Serological Markers and Test Interpretations
  • Table 3: Symptoms of HBV Infection
  • Table 4: HBV Vaccination Advisory Committees by Country
  • Table 5: HBV Immunization Recommendations by Country
  • Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
  • Table 7: Leading Vaccines for HBV, 2014
  • Table 8: Unmet Need and Opportunity in Prophylactic HBV Vaccines
  • Table 9: Product Profile - Heplisav
  • Table 10: Immunogenicity Profile - Heplisav
  • Table 11: Safety Profile - Heplisav
  • Table 12: Heplisav SWOT Analysis, 2014
  • Table 13: Global Sales Forecasts ($m) for Heplisav, 2012-2022
  • Table 14: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, by Country
  • Table 15: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, by Country
  • Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: HBV Structure and the Recombinant Vaccine Development Process
Back to Top